Loading...

PTCT PTC THERAPEUTICS INC Product Launches 8-K Filing

PTC

PTCT

PTC THERAPEUTICS INC

(PTCT)

2025 8-K

Drug Application Withdrawal

Financial Results Update

Royalty Sale Agreement

Financial Results Report

FDA Response Letter

Merger of Equals

Financial Statements

New Product Launches

Financial Statements

Investor Meetings

Milestone Payment

Earnings Report

Earnings Report

Earnings Update

New Partnership

Earnings Report

Earnings Report

Filing Letter with Quantita...

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Filing with Quantitative Data

Quantitative Data

Quantitative Data

Quantitative Data

Management Change

Quantitative Data

Filing with Quantitative Data

External Links:

On July 28, 2025, PTC Therapeutics, Inc. announced the FDA approval of Sephience™ (sepiapterin) for treating children and adults with phenylketonuria (PKU). This treatment is for patients aged one month and older who are responsive to sepiapterin.

AI Assistant

PTC THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.